Thema: US92243G1085
PCVX, US92243G1085
business-163870_1920.jpg - Foto: THN
Vaxcyte stock holds at EUR 55.75 in late Lang & Schwarz quote
The latest quote was unchanged from the previous close. The reading is a neutral late-session snapshot, not a new company disclosure.
ad-hoc-news.de, heute 00:09 Uhr
PCVX, US92243G1085
Cantor Fitzgerald sets USD 120 target for Vaxcyte stock
Vaxcyte lost USD 284.30 million in the second quarter. Vaxcyte stock costs EUR 58.75 on October 20, 2026 at 6:17 p.m. CEST.
ad-hoc-news.de, 20.10.26 18:31 Uhr
PCVX, US92243G1085
Cantor Fitzgerald sets USD 120.00 target for Vaxcyte stock ...
Second-quarter earnings per share showed a USD 1.97 loss. Vaxcyte stock costs USD 63.62 on October 16, 2026, down 2.53 percent versus its prior close.
ad-hoc-news.de, 17.10.26 19:10 Uhr
PCVX, US92243G1085
Vaxcyte stock rises 6.82 percent to EUR 58.75 after-hours ...
Vaxcyte stock costs EUR 58.75 on October 15, 2026, up 6.82 percent versus Frankfurt close. Cantor set a USD 120.00 target on October 12, 2026.
ad-hoc-news.de, 15.10.26 21:57 Uhr
PCVX, US92243G1085
Guggenheim raised target for Vaxcyte stock from USD 116.00 ...
Second-quarter earnings per share were USD -1.97 versus USD -2.06 consensus. Vaxcyte stock costs EUR 59.75 on October 8, 2026, above EUR 59.50.
ad-hoc-news.de, 08.10.26 13:00 Uhr
PCVX, US92243G1085
Vaxcyte stock reports OPUS-1 success after a 9.65 percent ...
Vaxcyte stock traded at USD 66.70 on October 6, 2026, while VAX-31 met 20 of 20 PCV20 comparisons. A USD 1 billion financing adds dilution risk.
ad-hoc-news.de, 07.10.26 05:18 Uhr
Institutional, Investors
Institutional Investors Bet Big on Vaxcyte’s Clinical ...
